Bryan Laskey

Senior Business Unit Director, Neuroscience & Rare Disease

Bryan Laskey joined Ipsen Canada in January 2024 as Senior Business Unit Director, Neuroscience & Rare Disease. In this role, Bryan is responsible for overseeing the commercial and cross-functional strategic and operational leadership within Ipsen’s Neuroscience & Rare Disease business unit. Bryan works to ensure that our sales and marketing teams continue to exceed customer expectations and perform at the highest level, in a highly collaborative manner.

Bryan is an accomplished sales and marketing leader with more than 30 years of pharmaceutical industry experience working across many different therapeutic areas. He has a proven track record of success and is a respected leader who takes great pride in developing people and inspiring teams. Prior to joining Ipsen, Bryan was Vice President of Sales and Marketing at GSK Canada. In this role, Bryan was responsible for leading the development and execution of brand strategy and marketing plans for numerous products in the GSK portfolio. Bryan started his career in Sales at GSK and subsequently worked in progressively more senior roles in sales, marketing, and market access.

Bryan has a Degree in Economics from McMaster University.

Our mission

To improve patients’ lives

Acting on this mission has propelled us to become a global biopharmaceutical leader with a focus on innovation and specialty care. We help patients through our expertise in oncology, neuroscience, and rare disease.

Find out more about us or see other members of our leadership team.

About

Products and partnerships

Our products

Our mission is to improve patients’ lives.

See our products

Partnering

Access our development and commercialization teams. We take bold steps to translate your science and innovations into solutions that make a difference for patients in need.

See more on partnering

Products and partnerships

What’s happening now?

See the latest
©2024 Ipsen Biopharmaceuticals, Inc. All rights reserved. June 2023 CR-CA-000013